Advice
Following a full submission
Montelukast (Singulair) is accepted for restricted use within NHS Scotland for the symptomatic relief of seasonal allergic rhinitis (SAR) in adult patients in whom montelukast is indicated in asthma, as add-on oral therapy at steps 3 and 4 of the BTS/SIGN asthma guidelines.
Other more effective and cost effective treatments for SAR are available for patients in whom montelukast is not required for the treatment of asthma.
Download detailed advice48KB (PDF)
Medicine details
- Medicine name:
- montelukast (Singulair)
- SMC ID:
- 185/05
- Indication:
- Seasonal allergic rhinitis in adult patients in whom montelukast is indicated in asthma
- Pharmaceutical company
- MSD
- BNF chapter
- Respiratory system
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 11 July 2005